Autism spectrum disorder (ASD) manifests with a striking disparity in incidence rates between males and females, with males receiving diagnoses approximately four times more frequently than females. This disparity has fueled long-standing hypotheses proposing intrinsic biological mechanisms within females that confer protection against the development of autism. However, empirical validation of these protective biological processes, particularly in the context of genetic mutations implicated in autism, has remained elusive until now. A groundbreaking study conducted through an international collaboration involving KAIST, Yonsei University, and the Institute for Basic Science has shed light on the complex interplay between mutation severity and sex-specific susceptibility in ASD.
Central to this pioneering research is the gene CHD8, a critical chromatin remodeler that regulates the transcriptional landscape of numerous genes involved in neurodevelopment. CHD8 mutations rank among the most significant genetic risk factors for ASD, influencing synaptic signaling, RNA splicing, and mitochondrial function—pathways deeply intertwined with the molecular etiology of autism and related neurodevelopmental disorders. While prior animal models carrying a heterozygous CHD8 mutation exhibited only mild phenotypic anomalies, severely limiting the exploration of more profound disease mechanisms, attempts to create homozygous mutants proved fatal, as embryos failed to survive. Overcoming this obstacle, the collaborative team engineered a novel viable homozygous CHD8 mutant mouse on a hybrid genetic background, permitting survival and enabling comprehensive studies of mutation severity.
This advanced mouse model has enabled the unprecedented examination of the differential phenotypic consequences of mild versus severe CHD8 mutations across sex lines—an aspect critical to understanding the sex-biased profile of autism. Investigations revealed that males harboring a mild mutation display behavioral and neurological abnormalities consistent with autism symptomatology, confirming previous observations and reflecting the human male bias in ASD diagnosis. Females with identical mild mutations, in contrast, exhibit a remarkable resilience attributed to a biological “female shield,” a temporary buffer mechanism that compensates for the genetic disruption and protects against overt autistic phenotypes. This observation confirms a dynamic protective capacity inherent in females rather than a static gender difference.
However, this biological safeguard is not immutable. The study unveiled that when the CHD8 mutation is intensified to a homozygous state, effectively doubling the genetic insult, the protective female shield collapses. Under these severe mutation conditions, both male and female mice manifest profound autism-related traits, including altered social behaviors and cognitive impairments, mirroring severe forms of ASD observed clinically. This finding importantly recalibrates our understanding of the sex difference in autism susceptibility, indicating that it is contingent upon the magnitude of genetic perturbation rather than being an absolute feature.
Beyond behavioral assessments, these genetically manipulated mice displayed significant neuroanatomical and physiological abnormalities. Enlarged brain volumes, disrupted cerebral blood flow, and aberrant neuronal oscillations were prominent in homozygous mutants, heralding dysfunctions within neural circuits crucial for cognitive processes. Additionally, transcriptomic analyses exposed extensive gene expression alterations involving synaptic signaling pathways, RNA splicing regulators, and mitochondrial bioenergetics. These molecular disruptions offer a mechanistic blueprint for the observed behavioral phenotypes and provide insight into the biological underpinnings of ASD’s heterogeneity.
The implication that sex differences in autism phenotypes are quantitatively modulated by genetic mutation severity redefines the conceptual framework for autism research. Rather than assuming fixed, binary sex-based vulnerabilities, this paradigm emphasizes a fluid spectrum where biological sex and genetic disruptions intersect synergistically. This nuanced perspective also extends its relevance to other neurodevelopmental disorders associated with CHD8 mutations, including attention deficit hyperactivity disorder (ADHD), intellectual disabilities, and schizophrenia, which also demonstrate sex-biased prevalence and may be influenced by mutation load.
Professor LEE Eunee from Yonsei University highlights the broader significance of these findings, emphasizing that the female biological shield’s existence informs why diagnostic and phenotypic patterns in autism differ across individuals and populations. She underscores the necessity of integrating consideration of both biological sex and mutation severity into clinical diagnostics, therapeutic development, and personalized medicine approaches for neurodevelopmental disorders. This research paves the way for future targeted interventions aimed at bolstering protective mechanisms or mitigating mutation severity.
Furthermore, Director KIM Eunjoon of the IBS Center for Synaptic Brain Dysfunctions articulates the transformative impact of this study. By successfully developing the viable homozygous CHD8 mutant mouse model, his team has achieved a milestone in dissecting the brain circuit and genetic mechanisms that drive severe autism. The revelation that sex differences in ASD phenotypes vary dynamically with genetic dosage establishes a foundational knowledge base for the precision therapeutics era, reinforcing the importance of individualized treatments tailored not just to genetic makeup but also to biological sex.
This research exemplifies the power of innovative genetic engineering combined with integrative behavioral, physiological, and molecular analyses to unravel intricate biological phenomena underlying complex neurodevelopmental disorders. It offers a clarion call for the scientific and medical communities to reevaluate clinical frameworks and encourages the continuous pursuit of mechanistically driven therapeutics that correspond to patients’ unique genetic and biological profiles.
The study was published in the esteemed journal Molecular Psychiatry on May 9th, 2026, and is expected to stimulate extensive follow-up research probing the molecular signatures of the female biological shield, the pathways mediating mutation-induced neuronal dysfunction, and the translational potential of these findings to human clinical populations.
Subject of Research: Animals
Article Title: Homozygous CHD8 mutation intensifies ASD phenotypes and attenuates sex differences
News Publication Date: 9-May-2026
Web References: 10.1038/s41380-026-03646-9
Image Credits: Institute for Basic Science
Keywords: Autism, Developmental disabilities, Mutation, Molecular genetics, Genetics, Developmental neuroscience, Brain development, Cognitive development, Intellectual disabilities, Learning disabilities, Attention deficit hyperactivity disorder, Mouse models, Animal models, Biological models, Computational biology
Tags: animal models for autism researchautism spectrum disorder genetic mutationsCHD8 gene autism riskchromatin remodeling in autismfemale protective mechanisms in autismgene mutation severity and autismmitochondrial dysfunction in ASDmolecular pathways in ASDneurodevelopmental disorder geneticsRNA splicing in neurodevelopmentsex differences in autism diagnosissynaptic signaling and autism
